MorphoSys Completes Sale of AbD Serotec to Bio-Rad
Complete the form below to unlock access to ALL audio articles.
MorphoSys AG has announced that the sale of its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc. has been completed.
All assets and liabilities of the AbD Serotec segment of MorphoSys AG as well as all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. have been transferred to Bio-Rad.
"We are delighted to have reached the closing of the transaction just a few weeks after the announcement was made. With the divestment of AbD Serotec completed, MorphoSys can devote 100% of its attention to building value in its core therapeutics business," commented Jens Holstein, Chief Financial Officer of MorphoSys AG.
